Tags : JAVELIN Ovarian PARP 100

Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100

Tuba Khan March 20, 2019

Shots: The termination is based on P-III JAVELIN Ovarian PARP 100 study (B9991030) results assessing Bavencio (avelumab) + CT followed by avelumab + Talzenna (talazoparib) vs PBO in 9,000 patients […]readmore

Tags : JAVELIN Ovarian PARP 100

Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : JAVELIN Ovarian PARP 100

Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company